JAMA Drug Pricing Studies: Moving The Needle Or Looking At The Past?
Executive Summary
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
You may also be interested in...
Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
Pharma Outpaces All Other Industries In US Federal Lobbying Spending
Over the past 20 years, the pharmaceutical industry has notched a series of wins with its extraordinary federal lobbying expenditures and campaign contributions. A new JAMA Internal Medicine study examines spending from 1999-2018.
How Big Pharma Profits Stack Up Against Other Industries
Research published in JAMA shows that the pharmaceutical industry outpaces other industries in the S&P 500 on several measures of profitability.